[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polyneuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polyneuropathy":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,79,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100442360","patisiran-lipid-nanoparticle-lnp-pregnancy-surveillance-program-100442360",false,"NCT05040373","Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program","Patisiran-LNP Pregnancy Surveillance Program","Inclusion Criteria:\n\n* Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy\n\nExclusion Criteria:\n\n* There are no exclusion criteria for participation in this program.","FEMALE",{"count":18,"type":19},10,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal\u002Fneonatal\u002Finfant outcomes in women exposed to patisiran-LNP.",[23,24],"Hereditary Transthyretin-mediated (hATTR) Amyloidosis","Polyneuropathy",[26,27,28,29,30],"Hereditary neuropathic amyloidosis","Familial amyloidosis","Amyloidosis","Amyloidosis senile","Cardiac amyloidosis","RECRUITING","2026-05-28",{"date":34,"type":35},"2026-06-01","ACTUAL",{"date":37,"type":35},"2020-08-01",{"date":39,"type":19},"2030-10-12",{"name":41,"class":42},"Alnylam Pharmaceuticals","INDUSTRY",7,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100604644","effects-of-resistance-exercises-in-hereditary-sensory-motor-neuropathy-charcot-marie-tooth-disease-100604644","NCT07152197","Effects of Resistance Exercises in Hereditary Sensory-Motor Neuropathy (Charcot-Marie-Tooth Disease)","Effects of a Resistance Exercise Training Program on Skeletal Muscle Quality, Functional Capacity, and Quality of Life in Young Individuals With and Without Hereditary Sensorimotor Polyneuropathy","PNP","Inclusion Criteria:\n\n* Men or women between 15 and 29 years of age with a diagnosis of hereditary sensorimotor polyneuropathy (HSPN) in any of its subtypes, living in the community (for experimental group).\n* Healthy men or women between 15 and 29 years of age living in the community (for control group).\n* Having active ankle movement within a range from plantarflexion to at least 0° of ankle dorsiflexion, allowing for strength training.\n\nExclusion Criteria:\n\n* Osteoarticular or mobility impairments that prevent safe performance of resistance exercise training (e.g., ankle arthrodesis).\n* Use of nutritional supplements that may affect skeletal muscle regulation (leucine, glutamine, casein, whey protein, fatty acids, creatine, among others).\n* Untreated and\u002For uncontrolled chronic diseases or intellectual disability.\n* History of surgery\n* Participation in a resistance exercise training program within the past 6 months.",true,"ALL","15 Years","29 Years",{"count":57,"type":19},22,"INTERVENTIONAL",[60],"NA","The goal of this clinical trial is to compare the effects of an 8-week resistance exercise training program on skeletal muscle quality, functional capacity, and quality of life in young individuals aged 15 to 29 years, with and without Hereditary Sensorimotor Polyneuropathy (HSPN).\n\nThe main questions to answer are:\n\nWhat is the effect of an 8-week resistance exercise training program on skeletal muscle quality, functional capacity, and quality of life in young individuals with and without HSPN?\n\nWill the percentage of improvement after the program be greater in participants with HSPN compared to those without, due to greater baseline alterations?\n\nResearchers will compare the resistance exercise training program with baseline conditions to determine its effectiveness in improving skeletal muscle quality, functional capacity, and quality of life.\n\nParticipants will undergo a supervised lower-limb resistance exercise program (3x\u002Fweek) for 8 weeks. The intervention will include progressive loads from 60% to 80% of 1-Repetition Maximum (1RM), with exercises targeting the major lower limb muscle groups. All participants will complete pre- and post-intervention evaluations, including ultrasound assessment of muscle architecture, functional capacity tests, strength measurements, body composition analysis, and quality of life questionnaires.",[24,63],"Charcot Marie Tooth Disease (CMT)",[63,65,66,67],"Resistance Training","Muscle Quality","Quality of Life","2025-09-21",{"date":70,"type":35},"2025-09-23",{"date":72,"type":35},"2025-09-20",{"date":74,"type":19},"2026-09-20",{"name":76,"class":77},"Universidad de La Frontera","OTHER",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":53,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":58,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":100},"100512316","prevalence-of-wild-type-ttr-cardiac-amyloidosis-in-patients-with-polyneuropathy-of-unknown-cause-100512316","NCT05950867","Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.","Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause: a Prospective Monocentric Study (CAP-TTR)","Inclusion Criteria:\n\n* Patients with chronic axonal length-dependent polyneuropathy (CAP) and\u002For small-fiber neuropathy (SFN) without well-defined etiology.\n* Age: \\>= 60 years\n* Male and female gender\n* Written informed consent\n\nExclusion Criteria:\n\n* Known cause of polyneuropathy\n* Other types of peripheral neuropathy than chronic axonal length-dependent polyneuropathy (CAP) and\u002For small-fiber neuropathy (SFN).\n* Patients younger than 60 years","60 Years",{"count":88,"type":19},150,[60],"To investigate to what extent chronic axonal length-dependent polyneuropathy (CAP) and\u002For small-fiber neuropathy (SFN) is part of early non-cardiac manifestations of wild-type TTR cardiac amyloidosis (wtTTR-CA).\n\nConsequently, explore whether this could ultimately lead to faster diagnosis and clinical outcome of wild-type TTR cardiac amyloidosis (wtTTR-CA).",[24,28],"2025-07-17",{"date":94,"type":35},"2025-07-22",{"date":96,"type":35},"2023-07-28",{"date":34,"type":19},{"name":99,"class":77},"Universitair Ziekenhuis Brussel",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":53,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":58,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":100},"100585640","a-new-cancer-rehabilitation-process-for-chemotherapy-induced-foot-neuropathy-using-orthopedic-devices-100585640","NCT06904989","A New Cancer Rehabilitation Process for Chemotherapy-Induced Foot Neuropathy Using Orthopedic Devices","Implementation and Evaluation of a New Cancer Rehabilitation Process for the Assessment and Treatment of Chemotherapy-Induced Foot Neuropathy - A Collaborative Project Between Oncology Clinic and Orthopedic Technology Department 2.0.","FOTNEV","Inclusion Criteria:\n\n* Patients with breast cancer receiving treatment at the Oncology Department, Sahlgrenska University Hospital (SU).\n* Have undergone treatment with taxanes.\n* Aged 18 years or older.\n* Able to understand spoken and written Swedish.\n* Patients who can ambulate with or without assistive walking devices.\n* CTCAE grading above 2 at a medical visit after completing treatment.\n\nExclusion Criteria:\n\n* Bilateral amputation at the thigh level.\n* Previously diagnosed neurological disease or neurological impairment affecting the feet.","18 Years",{"count":111,"type":19},40,[60],"The goal of this clinical study is to evaluate a new process for assessing and alleviating chemotherapy-induced peripheral neuropathy in the feet in patients treated with chemotherapy for early stage breast cancer. It will also compare two orthopedic interventions for symptom relief. The main questions it aims to answer are:\n\nCan an orthopedic silicone orthosis reduce chemotherapy-induced peripheral neuropathy symptoms in the feet? How does the effectiveness of the silicone orthosis compare to standard orthopedic treatment with insoles and shoes?\n\nParticipants will:\n\nUse either a silicone orthosis or standard orthopedic treatment Have contact with the clinic for assessments and follow-ups Report their symptoms and functional improvements over time",[24,115],"Breast Cancer",[117,118,119,115,120],"Chemotherapy-Induced Peripheral Neuropathy (CIPN)","Oncology Rehabilitation","Orthopedic Intervention","Orthopedic Insoles","2025-03-24",{"date":123,"type":35},"2025-04-01",{"date":125,"type":35},"2024-12-01",{"date":127,"type":19},"2025-10",{"name":129,"class":130},"Vastra Gotaland Region","OTHER_GOV"]